Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer

NCT01727089 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01727089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01727089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2012
Completion date
August 8, 2017
Enrollment
59 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, recurrent renal cell carcinoma, stage iv renal cell cancer, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma